New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials
LIXTE Biotechnology (NASDAQ:LIXT) announced the publication of significant findings in Nature journal that validate their ongoing clinical trials of LB-100 for ovarian and colorectal cancers. The study, led by researchers at MD Anderson Cancer Center, revealed that patients with PPP2R1A mutations showed improved survival rates with immune checkpoint therapy.
The company is currently conducting two clinical trials: one testing LB-100 with dostarlimab for Ovarian Clear Cell Carcinoma (OCCC) at MD Anderson and Northwestern University, and another evaluating LB-100 with atezolizumab for colon cancer at the Netherlands Cancer Institute. Initial results are expected in the second half of 2025.
LIXTE Biotechnology (NASDAQ:LIXT) ha annunciato la pubblicazione di risultati importanti sulla rivista Nature che confermano l'efficacia dei loro studi clinici in corso su LB-100 per i tumori ovarici e del colon-retto. Lo studio, guidato dai ricercatori del MD Anderson Cancer Center, ha evidenziato che i pazienti con mutazioni PPP2R1A presentano tassi di sopravvivenza migliorati con la terapia con inibitori del checkpoint immunitario.
L'azienda sta attualmente conducendo due studi clinici: uno che testa LB-100 in combinazione con dostarlimab per il carcinoma a cellule chiare ovarico (OCCC) presso MD Anderson e la Northwestern University, e un altro che valuta LB-100 con atezolizumab per il cancro del colon presso il Netherlands Cancer Institute. I primi risultati sono attesi nella seconda metà del 2025.
LIXTE Biotechnology (NASDAQ:LIXT) anunció la publicación de hallazgos significativos en la revista Nature que validan sus ensayos clínicos en curso con LB-100 para cánceres de ovario y colorrectal. El estudio, liderado por investigadores del MD Anderson Cancer Center, reveló que los pacientes con mutaciones PPP2R1A mostraron tasas de supervivencia mejoradas con la terapia de inhibidores de puntos de control inmunitarios.
La compañía está llevando a cabo dos ensayos clínicos: uno que prueba LB-100 con dostarlimab para carcinoma de células claras ovárico (OCCC) en MD Anderson y Northwestern University, y otro que evalúa LB-100 con atezolizumab para cáncer de colon en el Netherlands Cancer Institute. Se esperan resultados iniciales en la segunda mitad de 2025.
LIXTE Biotechnology (NASDAQ:LIXT)는 난소암 및 대장암 치료를 위한 LB-100 임상 시험의 진행을 확인하는 중요한 연구 결과를 Nature 저널에 발표했다고 밝혔습니다. MD Anderson 암 센터 연구진이 주도한 이 연구에서는 PPP2R1A 돌연변이 환자들이 면역관문 억제제 치료를 통해 생존율이 향상된 것으로 나타났습니다.
회사는 현재 두 가지 임상 시험을 진행 중입니다: 하나는 MD Anderson과 Northwestern 대학에서 난소 투명세포암(OCCC)을 대상으로 LB-100과 dostarlimab을 병용하는 시험이며, 다른 하나는 네덜란드 암 연구소에서 대장암을 대상으로 LB-100과 atezolizumab을 평가하는 시험입니다. 초기 결과는 2025년 하반기에 발표될 예정입니다.
LIXTE Biotechnology (NASDAQ:LIXT) a annoncé la publication de résultats importants dans la revue Nature validant leurs essais cliniques en cours sur LB-100 pour les cancers de l’ovaire et colorectal. L’étude, menée par des chercheurs du MD Anderson Cancer Center, a révélé que les patients porteurs de mutations PPP2R1A présentaient de meilleurs taux de survie avec la thérapie par inhibiteurs des points de contrôle immunitaire.
L’entreprise mène actuellement deux essais cliniques : l’un testant LB-100 avec dostarlimab pour le carcinome à cellules claires de l’ovaire (OCCC) au MD Anderson et à la Northwestern University, et l’autre évaluant LB-100 avec atezolizumab pour le cancer du côlon à l’Institut néerlandais du cancer. Les premiers résultats sont attendus dans la seconde moitié de 2025.
LIXTE Biotechnology (NASDAQ:LIXT) gab die Veröffentlichung bedeutender Ergebnisse in der Fachzeitschrift Nature bekannt, die ihre laufenden klinischen Studien mit LB-100 bei Eierstock- und Darmkrebs bestätigen. Die Studie, geleitet von Forschern des MD Anderson Cancer Center, zeigte, dass Patienten mit PPP2R1A-Mutationen verbesserte Überlebensraten bei einer Immun-Checkpoint-Therapie aufwiesen.
Das Unternehmen führt derzeit zwei klinische Studien durch: Eine testet LB-100 zusammen mit Dostarlimab bei Ovarial-Klarzelligem Karzinom (OCCC) am MD Anderson und der Northwestern University, die andere bewertet LB-100 mit Atezolizumab bei Darmkrebs am Netherlands Cancer Institute. Erste Ergebnisse werden für die zweite Hälfte des Jahres 2025 erwartet.
- Nature journal publication validates LIXTE's ongoing clinical trials approach
- Study shows significant survival improvement in patients with PPP2R1A mutations
- Collaboration with major pharmaceutical companies GSK and Roche
- First clinical results expected in second half of 2025
- PPP2R1A mutations are relatively uncommon in patients
- Clinical trial results are still pending and success is not guaranteed
Insights
Nature publication validates LIXTE's LB-100 approach to enhancing immunotherapy by targeting PP2A, with clinical trial results expected soon.
This publication in Nature represents a significant scientific validation for LIXTE's therapeutic approach. The study found that ovarian clear cell carcinoma (OCCC) patients with inactivating mutations in PPP2R1A - which naturally reduces protein phosphatase 2A (PP2A) activity - showed significantly better overall survival with immune checkpoint blockade therapy.
This is precisely the mechanism that LIXTE's LB-100 compound artificially creates by inhibiting PP2A. The research demonstrates that this inhibition enhances the interferon gamma response pathway, which is associated with improved responses to immune checkpoint inhibitors.
The clinical significance is substantial as LIXTE has two ongoing trials directly applying this mechanism: one combining LB-100 with GSK's dostarlimab (anti-PD1) in OCCC patients at MD Anderson and Northwestern, and another combining LB-100 with Roche's atezolizumab (anti-PDL1) in colorectal cancer patients at the Netherlands Cancer Institute.
What makes this particularly noteworthy is that while PPP2R1A mutations are naturally rare, LB-100 could potentially provide the same survival benefits to a much broader patient population by pharmaceutically targeting the same pathway. With first clinical results expected in the second half of 2025, this publication provides strong mechanistic support for LIXTE's therapeutic hypothesis in an extremely prestigious scientific journal, suggesting the approach has merit.
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response
with LIXTE’s Proprietary Compound LB100
PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists that validate LIXTE’s ongoing clinical trials with its proprietary compound LB100 for Ovarian and Colorectal cancers (https://www.nature.com/articles/s41586-025-09203-8).
A team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, studied survival outcomes of Ovarian Clear Cell Carcinoma (OCCC) patients treated with immune checkpoint blockade therapy (clinicaltrials.gov identifier: NCT03026062). The ;study showed that patients having tumors with inactivating mutations in PPP2R1A - the major scaffold subunit of protein phosphatase 2A (PP2A) - had significantly better overall survival, compared with patients who did not have this mutation in their tumors.
Inactivating mutations in PPP2R1A are known to reduce the enzymatic activity of PP2A, which is the target of LIXTE’s lead compound LB-100. Tumors with mutations in PPP2R1A were found to have increased the interferon gamma response pathway, which is known to be associated with improved immune checkpoint responses.
LIXTE is currently investigating the activity of LB-100 in combination with checkpoint immunotherapy in two clinical trials. The first is enrolling patients with OCCC, led by Dr. Jazaeri at MD Anderson Cancer Center, and also is open at Northwester University. In this trial, LIXTE is collaborating with GSK to test LB-100 in combination with dostarlimab (anti PD1). In the second trial, at the Netherlands Cancer Institute, LIXTE is collaborating with Roche to test LB-100 in combination with atezolizumab (anti PDL1) in colon cancer patients.
“Not only did we identify a new biomarker for improved survival with immunotherapy in ovarian cancer, but we also confirmed the correlation of this biomarker with survival benefit in other cancer types,” said Dr. Jazaeri, who was co-senior author of the Nature article. “Since PPP2R1A mutations are relatively uncommon, we believe the same benefits may be possible by targeting the PPP2A pathway using drugs, which we currently are evaluating in a clinical trial at MD Anderson.”
Bas van der Baan, LIXTE’s Chief Scientific Officer, added, “This work extends a body of pre-clinical evidence indicating that LB-100 is strongly synergistic with checkpoint immunotherapy in a range of cancer types. We look forward to the first results of our clinical studies in the second half of this year.”
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to obtain and maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information about LIXTE, Contact:
For more information about LIXTE, Contact: info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
FAQ
What did the Nature journal study reveal about LIXTE's LB-100 compound?
What clinical trials is LIXTE Biotechnology (LIXT) currently conducting?
Who are LIXTE's collaboration partners for the LB-100 clinical trials?
When will LIXTE (LIXT) announce the first results of their clinical studies?
What is the significance of PPP2R1A mutations in LIXTE's cancer research?
